Multidisciplinary Lifestyle Interventions for Neurological Disorders During the Silent Phase
NCT05984056 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2025-07-08
Summary
This clinical trial aims to test the impact of multidisciplinary lifestyle interventions (MLI) in neurologically healthy but at-risk individuals. It aims to find out:
* if giving four different kinds of lifestyle intervention and education slows down or reverses the expression of neurological disorder or their biomarkers.
* new biomarkers that either help in the early detection of neurological disease or identify the impact of various lifestyle interventions combined.
Participants will be randomized to the intervention or observation arm. Various biological samples and tests, along with survey questionnaires, will be performed at the time of entering the study, at 12 weeks after enrollment, and then at the end of the study at 12 months.
* Intervention arm: Participants will receive weekly, instructor-led intervention sessions (virtual group sessions) for 12 weeks. After the 12-week mark, participants will be encouraged to practice what they learned for nine more months.
* Observation arm: The intervention group will be compared to another group that did not get the intervention
Conditions
- Neurological Disorder
Interventions
- BEHAVIORAL
-
Multidisciplinary lifestyle interventions
Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
Sponsors & Collaborators
-
Ohio Department of higher education
collaborator UNKNOWN -
Vineet Punia MD
lead OTHER
Principal Investigators
-
Vineet Punia, MD · The Cleveland Clinic
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-07-13
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United States
Study Locations
More Related Trials
-
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
NCT00374075 ·Status: COMPLETED ·Phase: PHASE1
-
Dalfampridine and Gait in Spinocerebellar Ataxias
NCT01811706 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
NCT04973657 ·Status: COMPLETED ·Phase: PHASE1
-
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
NCT04302870 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
NCT01035671 ·Status: COMPLETED ·Phase: PHASE2
-
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
NCT00488839 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
NCT05573698 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
NCT01535664 ·Status: COMPLETED
-
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
NCT00557973 ·Status: COMPLETED ·Phase: PHASE2
-
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03127514 ·Status: COMPLETED ·Phase: PHASE2
-
Fenofibrate Treatment in SCI
NCT02455336 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
NCT01083667 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
NCT01898884 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.
NCT00605930 ·Status: COMPLETED ·Phase: NA
-
Dimethyl Fumarate in Adrenomyeloneuropathy
NCT06513533 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia
NCT01085903 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia
NCT00078481 ·Status: COMPLETED ·Phase: PHASE1
-
Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT02146378 ·Status: COMPLETED
-
Methylprednisolone Treatment of Friedreich Ataxia
NCT02424435 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
NCT07221240 ·Status: RECRUITING ·Phase: PHASE1
-
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
NCT02046434 ·Status: COMPLETED ·Phase: PHASE1
-
Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
NCT04742673 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Amivita in Amyotrophic Lateral Sclerosis
NCT03103815 ·Status: UNKNOWN ·Phase: NA
-
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
NCT05490563 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
NCT04253132 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2